Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel neuropeptide Y2 receptor agonists presented by Novartis

April 19, 2011

Amarin's phase III ANCHOR trial of AMR-101 meets primary endpoint

April 18, 2011

CHMP recommends approval of once-weekly exenatide for type 2 diabetes

April 18, 2011

Preclinical data suggest benefit of allopurinol in diabetes-related nephropathy

April 15, 2011

TAK-075 is a new, stable, orally active bone anabolic agent for osteoporosis

April 15, 2011

FDA sets PDUFA date for Teva Pharma's Bio-T-Gel NDA

April 14, 2011

Primary efficacy objective met in phase III GetGoal-S trial of lixisenatide in type 2 diabetes

April 13, 2011

PROLOR reports promising phase II results on hGH-CTP in growth hormone deficiency

April 12, 2011

Ferring presents new oxytocin OT receptor agonists

April 12, 2011

Roche discloses preclinical findings on new farnesoid X receptor agonists

April 12, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.